An exclusive agreement between CareDx, Inc. and Miromatrix Medical, Inc. has been announced with the goal of increasing the use of fully transplantable human bioengineered organs in the next wave of innovation. In order to assess acute allograft rejection in Miromatrix’s pipeline of human bioengineered organs non-invasively, CareDx will create an innovative testing solution for the company to use in pre-clinical animal models and will be the sole supplier of donor-derived cell-free DNA (dd-cfDNA) testing services for use in human clinical studies.
“With our partnership with Miromatrix, we are dedicated to being at the forefront of advancing the next wave of innovation to address the lack of organ supplies in transplantation. For the thousands of patients in need of a life-saving transplant, we hope that bioengineered organs will one day become a reality’, said Reg Seeto, CEO and president of CareDx. “We are happy to join with Miromatrix, a pioneer in the development of human bioengineered organs as they apply our expertise to enhance their clinical pipeline.”
According to Jeff Ross, Ph.D., CEO of Miromatrix, “CareDx is at the cutting edge of transplant innovation and has been essential in creating paradigm shifts in clinical practise through its non-invasive testing services, which are extensively employed by top organ transplant centres across the US.” “Our cooperation with CareDx allows us to tap into their knowledge in ways that may help us accelerate our momentum as we lead the next wave of innovation with bioengineered alternatives for use in human organ transplants,” says the company. The number of Americans waiting for organ transplants is thought to be over 100,000, yet just slightly more than half of them are anticipated to get an organ over the next five years. There are said to be 17 persons who pass away every day while awaiting an organ transplant.
CareDx, Inc., with its corporate office in Brisbane, California, is a market-leading provider of precision medicine solutions dedicated to the identification, creation, and commercialization of high-quality, clinically differentiated healthcare products for transplant recipients and their carers. A life sciences business called Miromatrix Medical Inc. is developing a unique technique for designing completely transplantable human organs to help preserve and enhance patients’ lives.
